Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study-Reference-Cited by-同舟云学术

Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study

Published:2021-08 Issue:8 Volume:43 Page:1419-1430
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Woo Jong Shin,Hong Soon Jun,Cha Dong Hoon,Kim Kee Sik,Kim Moo Hyun,Lee Jun-Won,Jeong Myung Ho,Jeong Jin-Ok,Lee Jun-Hee,Jeon Doo Soo,Cho Eun Joo,Kim Soon Kil,Kwan Jun,Park Chang Gyu,Lee Hae Young,Hong Taek Jong,Shin Jinho,Youn Ho Joong,Jeon Dong Woon,Chung Wook Jin,Jeong Ju Cheol,Kim Chong Jin

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference32 articles.

1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019

2. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Arnett;Circulation,2019

3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

4. Using mendelian randomization to determine causative factors in cardiovascular disease;Johansen;J Intern Med,2013

5. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction;Jorgensen;Eur Heart J,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects;Drug Design, Development and Therapy;2024-02

2. The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials;Frontiers in Nutrition;2022-10-13

3. Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers;Pharmaceuticals;2022-08-03